Haemonetics (NYSE:HAE) Issues Earnings Results

Haemonetics (NYSE:HAE) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06, FiscalAI reports. The business had revenue of $339.38 million for the quarter, compared to analysts’ expectations of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company’s revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.10 EPS.

Here are the key takeaways from Haemonetics’ conference call:

• Haemonetics raised fiscal 2027 guidance, now expecting reported revenue growth of 5%–8% and organic growth of 4%–7%, following first-quarter revenue growth of 6% and adjusted EPS growth of 4% to $1.14.
• Plasma revenue increased 8% organically, supported by double-digit disposable growth, share gains, strong collection volumes, and the early rollout of Persona PLUS, which is delivering more than 5% yield improvements for early adopters.
• Interventional technologies returned to growth, led by low-double-digit vascular closure growth. The VASCADE MVP XL indication expansion, new clinical evidence, and stronger sales execution are supporting account wins and increased utilization in PFA and other large-bore procedures.
• Cash generation was strong, with operating cash flow tripling year over year to $52 million and trailing-12-month free-cash-flow conversion reaching 106% of adjusted net income. The company used cash to repay $100 million of revolver debt and retains flexibility for growth investments and opportunistic share repurchases.
• External cost pressures remain a headwind, including tariffs, transportation and oil-related costs, material inflation, and higher personnel expenses. Slower cell-salvage capital upgrades and weakness in OEM and esophageal-cooling businesses also weighed on parts of MedSurg and interventional technologies.

Haemonetics Trading Up 2.9%

NYSE HAE traded up $2.48 during trading hours on Friday, hitting $87.50. 657,064 shares of the company were exchanged, compared to its average volume of 737,142. Haemonetics has a 52 week low of $47.31 and a 52 week high of $88.58. The company has a quick ratio of 1.87, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. The stock has a 50-day moving average price of $76.98 and a 200 day moving average price of $66.52. The stock has a market cap of $3.98 billion, a PE ratio of 42.89, a price-to-earnings-growth ratio of 1.71 and a beta of 0.52.

Institutional Trading of Haemonetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HAE. Virtu Financial LLC bought a new stake in Haemonetics in the fourth quarter worth about $452,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Haemonetics in the fourth quarter worth approximately $509,000. EP Wealth Advisors LLC bought a new stake in shares of Haemonetics during the 4th quarter worth approximately $288,000. Mackenzie Financial Corp bought a new stake in shares of Haemonetics during the 4th quarter worth approximately $244,000. Finally, XTX Topco Ltd grew its position in Haemonetics by 128.9% in the 4th quarter. XTX Topco Ltd now owns 11,199 shares of the medical instruments supplier’s stock valued at $898,000 after acquiring an additional 6,307 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on HAE. Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. Citigroup lifted their target price on shares of Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Friday. Mizuho increased their price target on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Robert W. Baird set a $96.00 target price on Haemonetics in a research report on Friday. Finally, JPMorgan Chase & Co. increased their price target on Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $90.89.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.